Indivior Pharmaceuticals Inc (INDV) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in North Chesterfield, VA, United States. Der aktuelle CEO ist Joseph J. Ciaffoni.
INDV hat IPO-Datum 2014-12-29, 1,030 Vollzeitbeschäftigte, gelistet an der NASDAQ Global Select, eine Marktkapitalisierung von $4.06B.
Indivior PLC is a specialty pharmaceutical company focused on developing and commercializing prescription medications for substance use disorders, serious mental illnesses, and opioid overdose. The company's marketed portfolio includes SUBLOCADE and SUBUTEX PRO, buprenorphine extended-release monthly injections; SUBOXONE sublingual films and tablets; SUBUTEX sublingual tablets; OPVEE nasal spray for opioid overdose reversal; and PERSERIS for schizophrenia treatment. Indivior maintains a robust pipeline with multiple clinical and preclinical programs, including INDV-2000 for opioid use disorder, INDV-1000 for alcohol use disorder, and several collaborative development programs addressing opioid, cannabis, and other substance use disorders. Headquartered in North Chesterfield, Virginia, the company operates across the United States, United Kingdom, and international markets.
